Quick Summary
Hormoclib 75mg Capsule
Last updated on 31 Mar 2026 | 09:30 AM (IST)
₹3516
MRP: ₹16770
(You Save ₹13254)
21 CAPSULE(s) IN A BOX
79% OFF
₹3516
MRP: ₹16,770.00
Inclusive of all taxes
79% Off
Product Discontinued
Substitutes
Palbokaas 75mg Capsule
ANAKAAS LIFE BI...
₹ 85.71/capsule
48% cheaper
Ciclib 75mg Capsule
SHILPA MEDICARE...
₹ 110.52/capsule
33% cheaper
Piclib 75mg Capsule
HETERO HEALTHCA...
₹ 115.43/capsule
31% cheaper
Palnat 75mg Capsule
NATCO PHARMA LT...
₹ 125.00/capsule
25% cheaper
Introduction
Hormoclib 75mg Palbociclib Capsule is a targeted cancer therapy that contains the active ingredient palbociclib. It belongs to a class of anticancer drugs known as cyclin-dependent kinase (CDK) inhibitors, which work by blocking specific proteins that help cancer cells grow and divide. This medicine is primarily used for Hormoclib 75mg breast cancer treatment, specifically in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer—a type that has spread beyond the original site.
Hormoclib 75 Capsule is not used alone; it is typically given in combination with hormonal therapies to improve treatment outcomes. This approach helps slow down the progression of cancer and may improve overall survival in eligible patients.
The Hormoclib capsule price can vary depending on the pharmacy, location, and availability. Patients are advised to consult a trusted healthcare provider or pharmacy to get accurate pricing and understand whether this treatment is right for their condition.
Uses
- Treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer.
How Hormoclib 75mg Capsule works
Hormoclib 75mg Capsule works by blocking the protein called cyclin-dependent kinases 4 and 6, which are vital for the division and growth of cells. By blocking these proteins, this medication slows the growth and prevents the cancer cells from spreading.
Interaction of Hormoclib 75mg Capsule with other drugs
Inform your doctor about all medications, including prescribed, over-the-counter, nutritional or vitamin supplements and herbal products that you are taking or have taken before the treatment. Concurrent use of Hormoclib 75mg Capsule with CYP3A4 inhibitors such as fentanyl has reported increased fentanyl toxicity. Certain medications may interact with the effectiveness of this drug.
Storage conditions
- Keep Hormoclib 75mg Capsule out of sight and reach of children.
- Store at 20°C to 25°C.
How to take Hormoclib 75mg Capsule
Take Hormoclib 75mg Capsule exactly as prescribed by your doctor. Take this medication once a day at the same time with food. Swallow this capsule as a whole with a glass of water. Avoid crushing, breaking, or chewing the capsule.
Safety Advice for Hormoclib 75mg Capsule
Breast Feeding
Hormoclib It is not recommended to take Hormoclib 75mg Capsule while breastfeeding as it is not known whether it passes into the breast milk.
Alcohol
It is unknown whether it is safe to drink alcohol while taking Hormoclib 75mg Capsule. Check with your doctor for advice.
Liver
Inform your physician if you have any liver disorders before taking Hormoclib 75mg Capsule, as it should be used with caution in liver disorder patients.
Lungs
It is not unknown whether Hormoclib 75mg Capsule can be administered to patients with lung problems. Consult your doctor if you have any lung diseases before starting the treatment.
Driving
Hormoclib 75mg Capsule can cause tiredness. Avoid driving if you are unwell
Pregnancy
It is not recommended to take Hormoclib 75mg Capsule during pregnancy as it can harm the unborn baby. Women with childbearing potential should use effective contraceptives during treatment and for at least three weeks after treatment.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them. Hormoclib 75mg side effects include
Serious:
- Blood disorder (fever, chills, shortness of breath, weakness, bleeding, or bruising)
- Lung inflammation (chest pain, dry cough, or difficulty breathing)
Common:
- Tiredness
- Hair loss
- Dry skin, rash
- Infections
- Low blood cell counts
- Decreased of appetite
- Nausea, vomiting
- Diarrhea
- Swelling of lips and mouth
- Changes in taste
- Nose bleed
- Dry eye, blurred vision, increased tearing
Expert Tips
-
Avoid grapefruit, grapefruit juice, and products containing St. John’s wort during Hormoclib 75mg Capsule treatment.
-
Use effective birth control:
-
For females: during treatment and for at least 3 weeks after the final dose.
-
For males: during treatment and for at least 14 weeks after the final dose.
-
-
This medicine may reduce fertility — discuss any concerns with your doctor before starting treatment.
-
Your doctor may recommend regular blood tests to monitor if Hormoclib 75mg Capsule is affecting your blood cell counts.
FAQs about Hormoclib 75mg Capsule
Q1.
Is Hormoclib 75mg Capsule targeted therapy?
Yes, Hormoclib 75mg Capsule is a targeted therapy. This medication belongs to the class of cyclin-dependent kinase inhibitors.
Q2.
Do you lose hair on Hormoclib 75mg Capsule?
Yes, Taking Hormoclib 75mg Capsule can cause hair loss or hair thinning. It is one of the side effects of this medication. Consult your doctor if any side effects disturb you.
Q3.
Can children use Hormoclib 75 mg?
No, Hormoclib 75mg Capsule is not recommended for adolescents and children under 18.
Q4.
Does Hormoclib 75mg Capsule affect fertility?
Yes, Hormoclib 75mg Capsule may reduce fertility in men. It may affect your ability to become a father and a child. Hence, men should consider sperm preservation before taking this medication.
Q5.
Does Hormoclib 75mg Capsule affect blood cell count?
Hormoclib 75mg Capsule might reduce the number of white blood cells and weaken the immune system. It could lead to an increase in the risk of infections. Regular blood tests while taking Hormoclib 75mg Capsule are advised.
Fact Box
|
Molecule name
| Palbociclib |
|
Therapeutic class |
Cyclin-dependent kinase inhibitor |
|
Pharmacological class |
Anti-Neoplastics |
|
Indications |
HR-positive, HER2-negative advanced or metastatic breast cancer |
References
- Pfizer Limited, Electronic medicines compendium (emc), [Revised on June 2021] [ Accessed on 26 Nov 2022], https://www.medicines.org.uk/emc/files/pil.4449.pdf
- Pfizer Labs, US Food and Drug Administration, [Revised on March 2017] [ Accessed on 26 Nov 2022], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf
- Neha S Mangini et al; Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer; The Annals of Pharmacotherapy; Published on Nov 2015; Accessed on 26/11/2022; https://pubmed.ncbi.nlm.nih.gov/26324355/
- Palbace; Pfizer; Revised on Oct 2021; Accessed on 26/11/2022; https://labeling.pfizer.com/ShowLabeling.aspx?id=14029
Disclaimer
MrMed’s primary intention is to ensure that its consumers get accurate and trustworthy information that is reviewed by experts. The contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
Did you find this information helpful?
Author Details
Written By
Sakshi Anil More
B. Pharm
Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 31 Mar 2026 | 09:30 AM (IST)
Want to know more?
Read Our Editorial Policy
